Abstract 1577
Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of cancer with a five-year survival rate that has remained below 10% for the past two decades. While immunotherapy-based treatment in recent years has demonstrated great success in stimulating anti-tumor T cell immunity in a wide variety of cancers, immunotherapy has had very limited success in pancreatic cancer patients. PDAC is characterized by a highly immunosuppressive tumor microenvironment (TME), dominated by Myeloid Derived Suppressor Cells (MDSCs), Type 2 Tumor-Associated Macrophages (M2 TAMs), and T regulatory cells (Tregs). While the presence of these cell types in the PDAC TME is well characterized, much still remains to be understood about how they function within the TME and how they co-operate with each other and tumor-resident lymphocytes to regulate antitumor immunity.
Methods
MultiOmyx™, a novel hyperplexed multi “omic” technology, enables visualization and characterization of multiple biomarkers on a single 4 μm tissue section. MultiOmyx protein immunofluorescence (IF) assays utilize a pair of directly conjugated Cyanine dye-labeled (Cy3, Cy5) antibodies per round of staining. Each round of staining is imaged and followed by novel dye inactivation chemistry, enabling repeated rounds of staining and deactivation for up to 60 protein biomarkers. In this study, MultiOmyx hyperplexed IF assay was utilized to measure CD11b, CD14, CD15, CD16, CD33, CD45RO, CD68, CD163, FoxP3, HLA-DR, Arginase1, PD-1, PD-L1, granzymeB, Ki67, and PanCK protein expression from a single 4 µm FFPE section.
Results
Using the MultiOmyx™ multiplexing assay in combination with proprietary algorithms for specific biomarker classification, we will report on the correlation between the presence of monocytic MDSCs (CD11b+CD33+CD14+CD15-HLA-DR-), granulocytic MDSCs (CD11b+CD33+CD15+CD14-HLA-DR-), M2-TAMs (CD68+CD163+), Tregs (CD3+CD4+FoxP3+) and the activation state of TILs, as well as their spatial relationship in tumor tissue from patients with PDAC.
Conclusions
Using the MultiOmyx™ multiplexing assay will allow us to analyze correlations between immunosuppressive cells and TILs in the pancreatic TME.
Clinical trial identification
Legal entity responsible for the study
NeoGenomics.
Funding
NeoGenomics, a Pharma and Clinical services company.
Editorial Acknowledgement
Disclosure
A. Juncker-Jensen, J. Fang, J. Kuo, M.L. Nagy, R.K. Padmanabhan, E. Leones, F. Sahafi, S. Zhu, Q. Au, N. Hoe, J. William: Employee: NeoGenomics.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract